 then you have the problem that obviously clinicians aren't blind. You know, if I sit next to Sarah as a clinician for hours and I maybe hold her hand or, you know, I know if Sarah receives MDMA or not. I mean, I shouldn't be able to tell. I'm not informed by the study protocol, obviously, right? It's meant to be double blind. I just checked the MAPS website today before the interview, and they still maintain that both trials are double blind. But of course, that's just not the case.